

# Overview of the restructuring

Previous chapter	New chapter	Title
C.1	C.1	EU GMP Guide: Introduction
	C.2	Directives to the EU GMP Guide
C.2	C.2.1	Commission Directive 2003/94/EC
C.3	C.2.2	Commission Directive 91/412/EEC
	C.3	EU GMP Guide Part I–IV
C.4	C.3.1	Part I – Basic Requirements for Medicinal Products
C.4.1	C.3.1.1	Chapter 1: Pharmaceutical Quality System
C.4.2	C.3.1.2	Chapter 2: Personnel
C.4.3	C.3.1.3	Chapter 3: Premises and Equipment
C.4.4	C.3.1.4	Chapter 4: Documentation
C.4.5	C.3.1.5	Chapter 5: Production
C.4.6	C.3.1.6	Chapter 6: Quality Control
C.4.7	C.3.1.7	Chapter 7: Outsourced Activities
C.4.8	C.3.1.8	Chapter 8: Complaints, Quality Defects and Product Recalls
C.4.9	C.3.1.9	Chapter 9: Self Inspection
C.5	C.3.2	EU GMP Guide Part II: Basic Requirements for Active Substances used as Starting Materials
C.8	C.3.3	Part III – GMP related documents
C.8.1	C.3.3.1	Explanatory Notes on the preparation of a Site Master File
C.8.2	C.3.3.2	Quality Risk Management (ICH Q9)
C.8.3	C.3.3.3	Pharmaceutical Quality System (ICH Q10)
C.8.4	C.3.3.4	Internationally harmonised requirements for batch certification
C.8.5	C.3.3.5	Template for the "written confirmation" for active substances exported to the European Union for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Previous chapter	New chapter	Title
C.8.5.1	C.3.3.5.1	Importation of Active Substances for Medicinal Products for Human Use Questions and Answers Version 7
C.8.7	C.3.3.6	Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use (Text with EEA relevance)
C.8.6	C.3.3.7	Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities
C.8.6.1	C.3.3.7.1	Questions and answers on implementation of risk-based prevention of cross-contamination in production and 'Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities' (EMA/CHMP/CVMP/SWP/169430/2012)
	C.3.4	EU GMP Guide Part IV – GMP-Requirements for Advanced Therapy Medicinal Products
C.22	C.3.4.1	Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products
C.6	C.4	EU GMP Guide Annexes
C.6.1	C.4.1	Annex 1 Manufacture of Sterile Medicinal Products
C.6.1.1	C.4.1.1	Annex 1 Draft Manufacture of Sterile Medicinal Products
C.6.2	C.4.2	Annex 2 Manufacture of Biological Active Substances and Medicinal Products for Human Use
C.6.3	C.4.3	Annex 3 Manufacture of Radiopharmaceuticals
C.6.4	C.4.4	Annex 4 Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products
C.6.5	C.4.5	Annex 5 Manufacture of Immunological Veterinary Medicinal Products
C.6.6	C.4.6	Annex 6 Manufacture of Medicinal Gases
C.6.7	C.4.7	Annex 7 Manufacture of Herbal Medicinal Products
C.6.8	C.4.8	Annex 8 Sampling of Starting and Packaging Materials
C.6.9	C.4.9	Annex 9 Manufacture of Liquids, Creams and Ointments

Previous chapter	New chapter	Title
C.6.10	C.4.10	Annex 10 Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation
C.6.11	C.4.11	Annex 11 Computerised Systems
C.6.12	C.4.12	Annex 12 Use of Ionising Radiation in the Manufacture of Medicinal Products
C.6.13	C.4.13	Annex 13 Investigational Medicinal Products
C.6.14	C.4.14	Annex 14 Manufacture of Medicinal Products Derived from Human Blood or Plasma
C.6.15	C.4.15	Annex 15 Qualification and Validation
C.6.16	C.4.16	Annex 16 Certification by a Qualified Person and Batch Release
C.6.17	C.4.17	Annex 17 Real Time Release Testing and Parametric Release
C.6.18	C.4.18	Annex 18 Good Manufacturing Practice for Active Pharmaceutical Ingredients
C.6.19	C.4.19	Annex 19 Reference and Retention Samples
C.7	C.5	Glossary
C.14	C.6.1	Guidelines on Good Distribution Practice of Medicinal Products for Human Use
C.14.1	C.6.1.1	Good Distribution Practice for Medicinal Products for Human Use – Questions and Answers
C.20	C.6.2	Guidelines on Principles of Good Distribution Practice of Active Substances for Medicinal Products for Human Use
C.10	C.7	Compilation of Community Procedures on Inspections and Exchange of Information
C.10.1	C.7.1	Conduct of Inspections of Pharmaceutical Manufacturers or Importers
C.10.2	C.7.2	Outline of a Procedure for Co-ordinating the Verification of the GMP Status of Manufacturers in Third Countries
C.10.3	C.7.3	Guideline on Training and Qualifications of GMP Inspectors

Previous chapter	New chapter	Title
C.10.4	C.7.4	Guidance on the occasions when it is appropriate for competent authorities to conduct inspections at the premises of manufacturers, importers and distributors of active substances and manufacturers or importers of excipients used as starting materials
C.10.5	C.7.5	The Issue and Update of GMP Certificates
C.10.6	C.7.6	A Model for Risk Based Planning for Inspections of Pharmaceutical Manufacturers
C.10.7	C.7.7	Procedure for dealing with serious GMP non-compliance requiring co-ordinated measures to protect public or animal health
C.10.8	C.7.8	Procedure for Dealing with Serious GMP Non-Compliance Information Originating from Third Country Authorities or International Organisations
C.10.9	C.7.9	Guideline on Training and Qualification of Inspectors Performing Inspections of Wholesale Distributors
C.10.10	C.7.10	GDP Inspection Procedure (Medicinal Products for Human Use)
C.10.11	C.7.11	The Issue and Update of GDP Certificates (Medicinal Products for Human Use)
C.12	C.8	Directive 2001/83/EC of the European Parliament and of the Council
C.12.1	C.8.1	Commission delegated regulation (EU) No 1252/2014
	C.8.2	Commission Delegated Regulation (EU) 2016/161
	C.9	Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products
C.11	C.10	EU Directives on Medical Devices
	C.10.1	Regulation (EU) 2017/745 of the European Parliament and of the Council
	C.10.2	Regulation (EU) 2017/746 of the European Parliament and of the Council

Previous chapter	New chapter	Title
C.11.1	C.10.3	Council Directive of 20 June 1990 on the approximation of the laws of the member states relating to active implantable medical devices (90/385/EEC)
C.11.2	C.10.4	Council Directive of 14 June 1993 concerning medical devices (93/42/EEC)
C.11.3	C.10.5	Directive of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (98/79/EC)
C.9	C.11	Note For Guidance on Quality of Water for Pharmaceutical Use
C.13	C.12	Guideline on Real Time Release Testing
C.15	C.13	Guideline on process validation for finished products – information and data to be provided in regulatory submissions
C.18	C.14	Guidance for the template for the qualified person's declaration concerning GMP compliance of active substance manufacture „The QP declaration template“
C.18.1	C.14.1	Qualified Person's declaration concerning GMP compliance of the active substance manufacture „The QP declaration template“
C.21	C.15	EMA: Data integrity Questions and Answers
C.16		Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms
C.17		Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work
C.19		Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances